https://scholars.lib.ntu.edu.tw/handle/123456789/503485
標題: | Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy | 作者: | Huang S.-H. SHU-WEN LIN SUI-YUAN CHANG Lin Y.-T. Chiang C. Hsiao C.-F. HSIN-YUN SUN Liu W.-C. Su Y.-C. CHIEN-CHING HUNG SHAN-CHWEN CHANG |
公開日期: | 2017 | 卷: | 7 | 期: | 1 | 起(迄)頁: | 16187 | 來源出版物: | Scientific Reports | 摘要: | We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their CYP2B6 516G>T polymorphism and efavirenz C12 determined. The median efavirenz C12 was 2.41 mg/L (IQR, 1.93-3.14). In analysis of covariance models, patients with CYP2B6 516GT and TT genotypes compared to those with GG genotype had higher efavirenz C12 (for GT genotype, an increase by 0.976 mg/L [95%CI, 0.765-1.188], and TT genotype, 4.871 mg/L [95%CI, 4.126-5.616]), while per 10-kg increment in weight decreased C12 by 0.199 mg/L (95%CI, 0.111-0.287). Models incorporating CYP2B6 516G>T polymorphism and weight had moderate predictive values in predicting efavirenz C12 ? 2 mg/L (ROC area under curve = 0.706 [95%CI, 0.656-0.756]). In the absence of CYP2B6 516G>T polymorphism, weight ?58 kg provided better predictabilities for efavirenz C12 ? 2 mg/L (probability, 77.1% [95%CI, 69.0-83.5%] for weight = 50 kg and 70.6% [95%CI, 64.1-76.4%] for weight = 58 kg). ? 2017 The Author(s). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/503485 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-017-16483-2 | SDG/關鍵字: | antiretrovirus agent; benzoxazine derivative; cytochrome P450 2B6; efavirenz; adult; blood; female; genetics; genotype; human; Human immunodeficiency virus infection; male; single nucleotide polymorphism; young adult; Adult; Anti-Retroviral Agents; Benzoxazines; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV Seropositivity; Humans; Male; Polymorphism, Single Nucleotide; Young Adult |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。